India very confident of doing well in the World Cup: Shikhar Dhawan

first_imgIndia very confident of doing well in the World Cup: Shikhar DhawanIndia opener Shikhar Dhawan said the top three, including himself, fellow opener Rohit Sharma and captain Virat Kohli, back themselves to get the job done at the top of the order.advertisement Press Trust of India ChennaiApril 30, 2019UPDATED: May 2, 2019 17:54 IST Shikhar Dhawan said India is confident of doing well at the 2019 World Cup (AP Photo)HIGHLIGHTSShikhar Dhawan played down India’s perceived over-reliance on the top orderWe back ourselves and are confident at the same time: Shikhar DhawanIndia begin their World Cup 2019 campaign on June 5 in SouthamptonFlamboyant opener Shikhar Dhawan on Tuesday said that the top three of Indian batting line-up, including himself, do not feel the added pressure going into the World Cup despite high expectations.He said the famed top-3 know how to go about their job in the World Cup starting on May 30.”I understand that everyone’s emotions are high, but high emotions are not going to win you matches. The confidence and calmness will. It is alright even if it is the World Cup. We are not going to over think it. We back ourselves and we are confident and calm at the same time,” Dhawan said when asked if there was pressure on Kohli, Rohit and himself to do the maximum run-scoring in the World Cup.”We have been doing well for five years now, so nothing is going to change. We have scored so many centuries, broken so many records, so we know how to do it,” said Dhawan ahead of his side Delhi Capitals’ IPL match against Chennai Super Kings here on Wednesday.It’s not just about the 3 of us: DhawanHe said India also have other top-class performers down the order to step up in case the top-order fails.”It is not just the three of us, the other boys have chipped in as well. There have been times when the three of us did not do well but Kedar (Jadhav), Mahi bhai (MS Dhoni) did the job. Hardik (Pandya) has been amazing and K L Rahul is there as well,” said Dhawan.advertisement”Vijay Shankar has come in, he’s a talented boy. So we have a great squad and we are very confident that we’re going to do great in the World Cup,” he said.Shreyas Iyer has been a great leader: DhawanThe left-handed batsman also said he was happy with the way he was playing in the ongoing IPL.Having qualified for the playoffs, Delhi are aiming for a top-2 spot.”We just have to play the same way because that is what has given us the success. Knockout is just a tag, obviously, if we win tomorrow’s game we directly go to the semi-finals, but nothing changes. We’re going to play the same way and back ourselves,” he said.He lauded Shreyas Iyer’s captaincy and said the Mumbai batsman was learning a lot from the high-pressure tournament.”He’s been a great leader, he’s learning a lot from this high pressure tournament. The way he has handled himself on the field is tremendous as a youngster. At the same time his strategic moves have been great as well.Also See:For sports news, updates, live scores and cricket fixtures, log on to indiatoday.in/sports. Like us on Facebook or follow us on Twitter for Sports news, scores and updates.Get real-time alerts and all the news on your phone with the all-new India Today app. Download from Post your comment Do You Like This Story? Awesome! Now share the story Too bad. Tell us what you didn’t like in the comments Posted byAkshay Ramesh Tags :Follow Shikhar DhawanFollow IPL 2019Follow 2019 World CupFollow India national cricket teamFollow Delhi CapitalsFollow Virat KohliFollow Rohit Sharmalast_img read more

Abbott Labs pleads guilty agrees to pay 15B for misbranding antiseizure drug

Abbott Labs pleads guilty, agrees to pay $1.5B for misbranding anti-seizure drug Depakote AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to RedditRedditShare to 電子郵件Email WASHINGTON – Abbott Laboratories has pleaded guilty and agreed to pay $1.5 billion over allegations that it promoted the anti-seizure drug Depakote for uses that were not approved by the Food and Drug Administration.The case includes a criminal fine and forfeiture of $700 million and civil settlements with the federal government and states totalling $800 million. Deputy Attorney General James Cole said Monday the settlement reflects the determination by government “to hold accountable those who commit fraud.”At a news conference at the Justice Department, U.S. Attorney Timothy Heaphy said that the top levels of Abbott carried out a strategy of systematically marketing the drug for purposes other than what federal regulators had allowed.The illegal conduct was not the product of “some rogue sales representatives,” said Heaphy, the U.S. attorney for the western district of Virginia. He said the company engaged in the strategy from 1998 to at least 2006.Separately, Virginia Attorney General Ken Cuccinelli announced a $100 million settlement with Abbott of consumer claims in 45 states and the District of Columbia. The consumer claims over Abbott’s promotion of Depakote for unapproved uses were brought under the Virginia Consumer Protection Act.Depakote is an anti-seizure and mood-stabilizing drug prescribed for bipolar disorder.However, the company admitted that it marketed the drug for unapproved uses, including treatment of schizophrenia, agitated dementia and autism.The company admitted that it trained a specialized sales force to promote Depakote in treating dementia because the drug was not subject to federal regulations designed to prevent the use of unnecessary medications in nursing homes.The company also marketed Depakote to treat schizophrenia. Clinical trials failed to demonstrate that adding Depakote was any more effective than antipsychotic drugs in treating schizophrenia, according to court papers in the case.Under the care of a physician, patients are sometimes prescribed drugs for purposes not approved by the FDA. However, pharmaceutical companies cannot market drugs for unapproved purposes.Illinois-based Abbott said the company was pleased to resolve the matter. It said that it takes its responsibility to patients and health care providers seriously. Under the settlement, the company has agreed to enter a five-year probationary period designed to ensure that there is no repeat of the company’s misconduct.Reuben Guttman, an attorney whose whistleblower clients brought Abbott’s activities to the attention of government investigators, said that the case shows how a company elevated aggressive sales and marketing of Depakote over medical decision-making. Abbott, said Guttman, “violated basic norms of health care and ethics.” by News Staff Posted May 7, 2012 7:21 pm MDT read more

Potash Corp of Saskatchewan reports lower Q2 net earnings lower sales

Potash Corp. of Saskatchewan reports lower Q2 net earnings, lower sales AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to RedditRedditShare to 電子郵件Email by The Canadian Press Posted Jul 24, 2014 7:23 am MDT SASKATOON – Potash Corp. of Saskatchewan (TSX:POT) raised its outlook for the year Thursday as it reported a second-quarter profit of $472 million.The company said its second-quarter profit amounted to 56 cents per diluted share, compared with $643 million, or 73 cents per share, in the same quarter of 2013.However, despite the drop, the results were better than PotashCorp’s guidance in April for a profit of 40 to 45 cents per share for the quarter.The average analyst estimate had been for a profit of 46 cents per share, according to Thomson Reuters.Sales for the global crop nutrient company were $1.89 billion versus $2.14 billion year-over-year.In its new outlook for the year, the company said it expected a profit for the full year of $1.70 to $1.90 per share, up from guidance in April for a profit of $1.50 to $1.80 per share.The new forecast is based on a third-quarter profit of 35 to 45 cents per share and annual potash sales of 8.9 million to 9.2 million tonnes.PotashCorp president and chief executive Jochen Tilk said robust global fertilizer demand helped the company’s results for the quarter.“Performance in all three nutrient segments improved from the beginning of the year and resulted in our second-quarter earnings exceeding the upper end of our guidance range,” Tilk said in a statement.“Although results were below those of the same period last year, an improving price environment and — in the case of our potash and nitrogen businesses — cost efficiencies contributed to our bottom line.”The price of potash was hit hard last year due to uncertainty caused by the collapse of a Russia-Belarus marketing cartel last August and lower customer demand amid China’s economic slowdown.PotashCorp said Thursday that its average realized potash price for the quarter was $263 per tonne, down from $356 per tonne in the same period last year.However, the company noted due to improving market fundamentals through the first half of this year the average realized price was up $13 per tonne relative to first-quarter 2014. read more